Disclosed Species Within A Count Establishes Constructive Reduction To Practice
Client Alert | 1 min read | 09.20.07
A Federal Circuit panel in Frazer v. Shlegel (No. 06-1154; August 20, 2007) reverses the Board of Patent Appeals and Interferences award of priority and remands the case to the U.S. Patent and Trademark Office. The Board held that Frazer was not entitled to the benefit of an early Australian application because the disclosure “did not provide a described and enabled anticipation under 35 U.S.C. § 102(g) of the subject matter of the count.” The Federal Circuit reverses, finding that Frazer is entitled to the priority date of the Australian patent application. In particular, the Federal Circuit determines that “the Australian application contained complete details of the method that is the subject of the interference count, and depicts the [virus] particle of the count with full disclosure of how to produce it.” As such, the panel concludes that the Australian application’s “description of the procedures used, and the successful production of the virus-like particles there achieved and reported, disclose and enable a species within the count.” Thus, the Board erred in ruling that Frazer’s Australian application did not prove conception of a species within the count. Frazer’s Australian application was thus a constructive reduction to practice of the invention and Frazer is entitled to the priority benefit of the Australian filing date.
Insights
Client Alert | 7 min read | 10.21.26
Securities Law for Entrepreneurs
Do you want your startup to expand and become a major player in your industry? If so, you will most likely need to seek capital from outside investors to help you build infrastructure and fulfill orders.
Client Alert | 5 min read | 10.06.26
Final adoption of Book 7 of the Belgian Civil Code and what this means for Construction Contracts
Client Alert | 7 min read | 10.05.26
Florida Court Upholds CMS Rule on Organ Procurement Organizations
Client Alert | 5 min read | 10.05.26
Generally Recognized as Safe: Key Changes to FDA’s GRAS Notification Requirement Looming
